Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a good deal for BMY or TSVT.

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly all of its market value.

CAMBRIDGE, Mass., March 11, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.

Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares up 76% in premarket trading on Tuesday.

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. | More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma,

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.

Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.

Fintel reports that on March 11, 2025, Leerink Partners downgraded their outlook for 2seventy bio (NasdaqGS:TSVT) from Outperform to Market Perform. Analyst Price Forecast Suggests 136.79% Upside As of March 4,

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio